Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes

Imagem de Miniatura
Arquivos
art_RAVANINI_Combined_use_of_immunohistochemical_markers_of_basal_and_2021.PDF (760.39 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2021
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
Citação
CLINICS, v.76, article ID e2587, 8p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: Whole genome expression profiles allow the stratification of bladder urothelial carcinoma into basal and luminal subtypes which differ in histological patterns and clinical behavior. Morpho-molecular studies have resulted in the discovery of immunohistochemical markers that might enable discrimination between these two major phenotypes of urothelial carcinoma. METHODS: We used two combinations of immunohistochemical markers, i.e., cytokeratin (CK) 5 with CK20 and CK5 with GATA3, to distinguish subtypes, and investigated their association with clinicopathological features, presence of histological variants, and outcomes. Upon searching for tumor heterogeneity, we compared the findings of primary tumors with their matched lymph node metastases. We collected data from 183 patients who underwent cystectomy for high-grade muscle-invasive urothelial carcinoma, and representative areas from the tumors and from 76 lymph node metastasis were organized in tissue microarrays. RESULTS: Basal immunohistochemical subtype (CK5 positive and CK20 negative, or CK5 positive and GATA3 negative) was associated with the squamous variant. The luminal immunohistochemical subtype (CK5 negative and CK20 positive, or CK5 negative and GATA3 positive) was associated with micropapillary and plasmacytoid variants. Remarkably, only moderate agreement was found between the immunohistochemical subtypes identified in bladder tumors and their lymph node metastasis. No significant difference in survival was observed when using either combination of the markers. CONCLUSION: This study demonstrates that these three routinely used immunohistochemical markers could be used to stratify urothelial carcinomas of the bladder into basal and luminal subtypes, which are associated with several differences in clinicopathological features.
Palavras-chave
Carcinoma, Urinary Bladder, Cystectomy, Histologic Variants, Tissue Microarray, Immunohistochemistry
URI
https://observatorio.fm.usp.br/handle/OPI/40847
Referências
  1. Al-Ahmadie H, 2020, ADV ANAT PATHOL, V27, P36, DOI 10.1097/PAP.0000000000000252
  2. Audenet F, 2018, UROL ONCOL-SEMIN ORI, V36, P313, DOI 10.1016/j.urolonc.2018.02.017
  3. Cheng L, 1999, CANCER, V85, P2638, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2638::AID-CNCR21>3.0.CO;2-V
  4. Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009
  5. Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036
  6. Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111
  7. Eble J, 2004, PATHOLOGY GENETICS T, V1
  8. Edge SB., 2010, AJCC CANC STAGING MA
  9. Greenson JK, 2009, AM J SURG PATHOL, V33, P126, DOI 10.1097/PAS.0b013e31817ec2b1
  10. Guo CC, 2016, EUR UROL, V70, P611, DOI 10.1016/j.eururo.2016.02.056
  11. Kamoun A, 2020, EUR UROL, V77, P420, DOI 10.1016/j.eururo.2019.09.006
  12. Lindgren D, 2010, CANCER RES, V70, P3463, DOI 10.1158/0008-5472.CAN-09-4213
  13. Lopez-Beltran A, 2019, HISTOPATHOLOGY, V74, P77, DOI 10.1111/his.13752
  14. Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007
  15. Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
  16. Sikic D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179602
  17. Sjodahl G, 2018, MODERN PATHOL, V31, P1869, DOI 10.1038/s41379-018-0096-5
  18. Sjodahl G, 2017, J PATHOL, V242, P113, DOI 10.1002/path.4886
  19. Sjodahl G, 2013, AM J PATHOL, V183, P681, DOI 10.1016/j.ajpath.2013.05.013
  20. Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T
  21. Smith AB, 2014, BJU INT, V114, P719, DOI 10.1111/bju.12601
  22. Thomsen MBH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11291-0
  23. Warrick JI, 2019, EUR UROL, V75, P18, DOI 10.1016/j.eururo.2018.09.003
  24. Warrick JI, 2017, VIRCHOWS ARCH, V471, P337, DOI 10.1007/s00428-017-2190-3
  25. Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
  26. Yang Y, 2020, UROL ONCOL-SEMIN ORI, V38, P449, DOI 10.1016/j.urolonc.2019.10.013

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03